My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Anavex Life Sciences Corp. - Common Stock (NQ:AVXL)

3.930 +0.010 (+0.26%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Anavex Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 28, 2022

Via Benzinga

Dow Tumbles Over 200 Points; Axsome Therapeutics Shares Spike Higher ↗

November 28, 2022

U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Monday.

Via Benzinga

CinCor Pharma, Anavex Life Sciences And Some Other Big Stocks Moving Lower On Monday ↗

November 28, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Earnings Scheduled For November 28, 2022 ↗

November 28, 2022

Companies Reporting Before The Bell • Pinduoduo (NASDAQ:PDD) is projected to report quarterly earnings at $0.65 per share on revenue of $4.31 billion.

Via Benzinga

Earnings Preview: Anavex Life Sciences ↗

November 25, 2022

Via Benzinga

Recap: Anavex Life Sciences Q1 Earnings ↗

February 09, 2022

Anavex Life Sciences (NASDAQ:AVXL) reported its Q1 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 9, 2022 ↗

February 09, 2022

Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion.

Via Benzinga

Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals ↗

February 01, 2022

Anavex Life Sciences Corp (NASDAQ: AVXL) reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome.

Via Benzinga

This Stock Is Up 106% In 2022 And Analysts Love It, But Jim Cramer Says 'There's Too Much Political Risk' ↗

November 15, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is a "very early stage company that has a lot in the pipe. I tend to like these companies."

Via Benzinga

Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday ↗

July 19, 2022

Gainers AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 14, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗

June 23, 2022

Upgrades

Via Benzinga

Anavex: Alzheimer's To Parkinson's Dementia ↗

April 15, 2022

Following a huge gain in 2021 (after a big gain in 2020), the shares have given back 27% year-to-date as investors ride out a quiet stretch awaiting trial results.

Via Talk Markets

Anavex Life Sciences Highlights Biomarker Data From Parkinson's Disease Dementia At International Conference ↗

March 15, 2022

Via Benzinga

The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗

February 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

23 Stocks Moving in Wednesday's Pre-Market Session ↗

February 02, 2022

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out: Executives buy more than $600 million of 3...

Via Benzinga

52 Biggest Movers From Yesterday ↗

February 02, 2022

Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969. Synaptogenix, Inc. (NASDAQ: SNPX) climbed 29.4% to close at $10.09. Synaptogenix...

Via Benzinga

Mid-Afternoon Market Update: Dow Rises 50 Points; DLH Holdings Shares Drop ↗

February 01, 2022

US stocks traded mixed in the afternoon session on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses.

Via Benzinga

Anavex Life Sciences Crashes As Last-Minute Testing Edits Cloud Drug's Impact ↗

February 01, 2022

Just two weeks ago, Anavex edited the goals of its study in Rett syndrome.

Via Investor's Business Daily

34 Stocks Moving In Tuesday's Mid-Day Session ↗

February 01, 2022

Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 01, 2022

Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K...

Via Benzinga

Mid-Day Market Update: Pitney Bowes Drops After Q4 Earnings; Biofrontera Shares Climb ↗

February 01, 2022

US stocks traded mostly flat on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses.

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower Following Monday's Rally; UPS Earnings Top Views ↗

February 01, 2022

US stocks started the first trading day of new month on a cautious note after recording gains on Monday. Wall Street closed the volatile January month with steep losses.

Via Benzinga

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗

February 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 14, 2022

Gainers Molecular Partners (NASDAQ:MOLN) shares moved upwards by 11.9% to $31.66 during Friday's pre-market session. The market value of their outstanding shares is at...

Via Benzinga

Anavex Life's Neurodegenerative Disease Candidate Meets Primary Endpoint In Early-Stage Study ↗

January 10, 2022

Anavex Life Sciences Corp (NASDAQ: AVXL) announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including...

Via Benzinga

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key...

Via Talk Markets

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 24, 2021

Gainers iSpecimen (NASDAQ:ISPC) shares in...

Via Benzinga

The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension ↗

November 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...

Via Benzinga

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.